Helicobacter Pylori Diagnostics Market – Quick Tests Allowing Efficient Diagnosis By Leading Companies: Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd

Market players are investing in developing point-of-care and accurate diagnostics products to gain competitive advantage. For instance, in 2017, Exaleza Bioscience launched Automated BreathID Hp Lab Urea Breath Testing System for detection of Helicobacter pylori. The system is point-of-care, with 99% sensitivity and specificity for H. pylori. Furthermore, companies are focusing enhancing product portfolio through inorganic growth strategies.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1874

For instance, Abbott Laboratories acquired Alere Inc., the global leader in point of care diagnostics, in order to expand its product portfolio and geographic presence. With this acquisition, Abbott could access to Alere’s rapid diagnostics segment, which includes H. pylori detection kits. However, limitations associated with the currently available diagnostic assays are expected to restrain the Helicobacter pylori diagnostics market. For instance, urea breath test and stool antigen test cannot be used in patients undergoing proton pump inhibitors treatment.

Prevalence of helicobacter pylori is declining in developed countries, whereas its prevalence in emerging economies is increasing. For instance, according to the Faculty of Medicine of The Chinese University of Hong Kong (CUHK), 2017, around 4.4 billion people worldwide are infected with Helicobacter pylori (H. pylori). Furthermore, same source suggested that prevalence in Africa is up to 80%, which is the highest globally, while in Asia, over 50% of the population was infected with H. pylori. Moreover, according to the International Agency for Research on Cancer report 2014, in 2012, around 952,000 new gastric cancer cases occurred globally and around 734,000 gastric cancers were estimated to occur due to H. pylori infection. Such high prevalence of Helicobacter pylori in Africa and Asia is expected to fuel the regional helicobacter market growth.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/1874

Moreover, Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS), an independent body reporting to the Quebec Minister of Health and Social Services, recommends the 13C-urea breath test to be made available in all areas of Québec. However, Africa Helicobacter pylori diagnostic market is expected to exhibit high CAGR, owing to high prevalence of Helicobacter pylori. According to studies published in Gastroenterology Journal, 2017, the data suggested that Africa has highest prevalence of H. pylori infection, which is around 79%.

Key players involved in the global Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd.(Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/1874

Manufacturers are focusing on inorganic strategies, in order to enhance their product offerings. For instance, Diasorin S.P.A., in September 2017, acquired ELISA technology business from Siemens, with an aim of shifting the current client base that uses ELISA tests towards CLIA technology solutions. As a part of agreement, Siemens will continue to manufacture and supply ELISA immunodiagnostic kits exclusively for DiaSorin for the next three years.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.